Experience of using the russian dipeptidyl peptidase-4 inhibitor gosogliptin. Results of the ONYX study

• Natalya A. Chernikova
• Alexander S. Ametov

Abstract

The choice of tactics for the treatment of type 2 diabetes mellitus is personalized, based on the clinical condition of the patient. Of the 9 classes of antidiabetic drugs used, dipeptidyl peptidase-4 (iDPP-4) inhibitors have become firmly established in medical practice about 15 years ago. Today, this group of drugs is confidently prescribed in the first lines of therapy for type 2 diabetes mellitus. DPP-4 inhibitors have a sugar-lowering effect by reducing fasting and postprandial hyperglycemia, do not cause weight gain, and have a favorable side effect profile. New representatives of this class appear annually. For example, in the Russian Federation, since 2016, the domestic i-DPP-4 - gosogliptin - has been used. This article presents the results of the ONYX study using gosogliptin.

Keywords:dipeptidyl peptidase-4 inhibitors, type 2 diabetes mellitus, type 2 diabetes, gosogliptin

References

1. International Diabetes Federation. IDF Diabetic Atlas. 8^th ed. 2017. URL: https://www.diabetesatlas.org/ (date of access April, 2019)

2. Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Atlas of the register of diabetes mellitus of the Russian Federation. Status 2018. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (2S): 4-61. (in Russian)

3. Algorithms of specialized medical care for patients with diabetes mellitus. In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov. (eds). 9^th is. Moscow, 2019. (in Russian)

4. Chernikova N.A. Knyshenko O.A. Modern approaches to the choice of hypoglycemic therapy in patients with type 2 diabetes mellitus: the niche of DPP-4 inhibitors. Farmateka [Pharmateca]. 2020; 27 (4): 33-9. (in Russian)

5. Cahn A., Cernea S., Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016; 21 (4): 409-19. DOI: https://doi.org/10.1080/14728214.2016.1257608

6. Ametov A.S. The state register of diabetes mellitus should become an instrument of import substitution. Remedium. 2018; (11): 25-8. URL: http://www.remedium-journal.ru/upload/iblock/624/RM_011_2018_4.pdf (in Russian)

7. Andrianova G.N., Petrov A.L., Kovtun O.P. Recommendations on the inclusion of the drug gozogliptin in the list of vital and essential medicines. 2018. URL: https://www.endocrincentr.ru/sites/default/files/all/koordinat-sionnyy_sovet/2/2%20%D0%93%D0%BE%D0%B7%D0%BE%D0%B3%D0%BB%D0%B8%D0%BF%D1%82%D0%B8%D0%BD.pdf (in Russian)

8. Galstyan K.O., Nedosugova L.V., Petunina N.A., Trakhtenberg Yu.A., Vostokova N.V., Karavaeva O.V., et al. First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients. Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (1): 89-96. DOI: https://doi.org/10.14341/DM7233 (in Russian)

9. Biryukova E.V. Clinical aspects and prospects for the use of DPP-4 inhibitors. Meditsinskiy sovet [Medical Council]. 2019; (4): 24-9. URL: https://www.medsovet.pro/jour/article/view/3111/3029 (in Russian)

10. Ametov A.S., Chernikova N.A., Knyshenko O.A. Dipeptidyl peptidase-4 inhibitors in modern Russian practice. Meditsinskiy sovet [Medical Council]. 2020; (7): 14-8. (in Russian)

11. Karagiannis T., Paschos P, Paletas K., et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012; 344: e1369. DOI: https://doi.org/10.1136/bmj.e1369

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)